logo-loader

Race Oncology with Proactive at the ASX Small and Mid-Cap Conference

Published: 12:41 16 Mar 2022 AEDT

Race Oncology Ltd (ASX:RAC)'s Phillip Lynch speaks with Proactive during the ASX Small and Mid-Cap Conference. They're a precision oncology company with a cancer drug called Zantrene®. It's a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers.

Race Oncology looks to accelerate clinical development of bisantrene

Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bisantrene,...

1 month, 1 day ago